Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2487-2495

  Nie, Danian ^a   Huang, Kezhi ^a   Yin, Songmei ^a   Li, Yiqing ^a   Xie, Shuangfeng ^a   Ma, Liping ^a   Wang, Xiuju ^a   Wu, Yudan ^a   Xiao, Jie ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Bortezomib; Cyclin D1; Drug resistance; Telomerase; Valproic acid

Indexed keywords

BORTEZOMIB; CYCLIN D1; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DRUG SYNERGISM; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOID; PROTEASOME INHIBITORS; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; VALPROIC ACID;

EID: 84868352661     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.698273     Document Type: Article

References (39)

1. Gul H, Marquez-Curtis LA, Jahroudi N, et al. Valproic acid exerts differential effects on CXCR 4 expression in leukemic cells. Leuk Res 2010; 34 :235-242.
2. Lu X, Ohata K, Kondo Y, et al. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 2010; 101: 609-615.
3. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269: 7-17.
4. Kircher B, Schumacher P, Petzer A, et al. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph AL L and CM L cells in vitro. Eur J Haematol 2009; 83: 48-56.
5. Hauswald S, Duque-Afonso J, Wagner MM, et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple AB C transporter genes. Clin Cancer Res 2009; 15: 3705-3715.
6. Lane S, Gill D, McMillan NA, et al. Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leuk Lymphoma 2012; 53: 1077-1083.
7. Brennan SK, Meade B, Wang Q, et al. Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood 2010; 116: 4185-4191.
8. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of onceweekly bortezomib in multiple myeloma patients. Blood 2010; 116: 4745-4753.
9. Colado E, Alvarez-Fernandez S, Maiso P, et al. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD 34 immature phenotype. Haematologica 2008; 93: 57-66. (Pubitemid 351156152)
10. Hu X, Xu J, Sun A, et al. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-kB activity. Leuk Lymphoma 2011; 52: 2393-2395.
11. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371-3376. (Pubitemid 38685442)
12. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065.
13. Heider U, Rademacher J, Lamottke B, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol 2009; 82: 440-449.
14. Zhang QL, Wang L, Zhang YW, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009;23: 1507-1514.
15. Wang AH, Wei L, Chen L, et al. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. Ann Hematol 2011; 90: 917-931.
16. Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI 571 in combination with commonly used antileukemic agents. Blood 2001;97: 1999-2007. (Pubitemid 32239079)
17. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
18. Kaiser M, Zavrski I, Sterz J, et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006;91: 248-251.
19. Shah P, Mato A, Luger SM. Valproic acid for the treatment of myeloid malignancies. Cancer 2008; 112: 2324-2325; author reply 2325. (Pubitemid 351628647)
20. Schwartz C, Palissot V, Aouali N, et al. Valproic acid induces nonapoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol 2007; 30: 573-582.
21. Arato-Ohshima T, Sawa H. O ver-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer 1999; 83: 387-392. (Pubitemid 29455763)
22. Xiao J, Yin S, Li Y, et al. SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 699-708.
23. Aref S, Mabed M, El-Sherbiny M, et al. Cyclin D 1 expression in acute leukemia. Hematology 2006; 11: 31-34.
24. Sakajiri S, Kumagai T, Kawamata N, et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005; 33: 53-61. (Pubitemid 40127644)
25. Kawamata N, Chen J, Koeffl er HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007; 110: 2667-2673. (Pubitemid 47523191)
26. Duan J, Friedman J, Nottingham L, et al. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6: 37-50. (Pubitemid 46206667)
27. Siitonen T, Koistinen P, Savolainen ER. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells. Leuk Res 2005; 29: 1335-1342. (Pubitemid 41297646)
28. Ishii Y, Pirkmaier A, Alvarez JV, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006; 98: 1238-1247. (Pubitemid 44390994)
29. Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl cells sensitive and resistant to STI571. Blood 2003; 102: 3765-3774. (Pubitemid 37409399)
30. Smith V, Dai F, Spitz M, et al. Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents. J Chemother 2009; 21: 542-549.
31. Akiyama M, Yamada O, Kanda N, et al. Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett 2002; 178: 187-197. (Pubitemid 34178544)
32. Tentori L, Portarena I, Barbarino M, et al. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor. Mol Pharmacol 2003; 63: 192-202. (Pubitemid 36043823)
33. Rahman R, Osteso-Ibanez T, Hirst RA, et al. Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. Mol Cancer Ther 2010; 9: 2568-2581.
34. Khaw AK, Silasudjana M, Banerjee B, et al. Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells. Mutat Res 2007;625: 134-144. (Pubitemid 350016112)
35. Pellicciotta I, Cortez-Gonzalez X, Sasik R, et al. Presentation of telomerase reverse transcriptase, a self-tumor antigen, is downregulated by histone deacetylase inhibition. Cancer Res 2008;68: 8085-8093.
36. Mukhopadhyay NK, Gordon GJ, Maulik G, et al. Histone deacetylation is directly involved in desilencing the expression of the catalytic subunit of telomerase in normal lung fibroblast. J Cell Mol Med 2005; 9: 662-669. (Pubitemid 44151953)
37. Hou M, Wang X, Popov N, et al. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 2002;274: 25-34.
38. Zhang W, Tong Q, Li S, et al. MG-132 inhibits telomerase activity, induces apoptosis and G(1) arrest associated with upregulated p27kip1 expression and downregulated survivin expression in gastric carcinoma cells. Cancer Invest 2008; 26: 1032-1036.
39. Natarajan M, Mohan S, Konopinski R, et al. Induced telomerase activity in primary aortic endothelial cells by low-LET gamma-radiation is mediated through NF-kappaB activation. Br J Radiol 2008;81: 711-720.